Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bydureon Approval Provides Lesson In Clinical Data Requirements For Biosimilars

Jul 01 2012

• By Sue Sutter

Related Content

Amylin Plans Cardiac Safety Study By The Book After Bydureon Rejection

Oct 25 2010

FDA's "Complete Response" Letter For Byetta LAR Isn't Too Onerous, Amylin Says

Mar 15 2010

<em>Bydureon</em> Clinical Development

Jul 01 2012

<em>Bydureon</em> Review Documents Paint An Unflattering Portrait Of Amylin

Jul 01 2012

Biosimilar Guidance Comments Reveal Small Window Of Agreement On Foreign Data

Apr 23 2012

Good News For A Change At Genzyme: Consent Decree Finalized Without Surprises, Lumizyme Approved By FDA Ahead Of Schedule

May 31 2010

FDA To Genzyme: Another Myozyme BLA, Please

Apr 21 2008

Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

Nov 08 2011

Genentech’s <em>Perjeta</em> Clears FDA Despite Unresolved Manufacturing Issues

Jun 18 2012

Related Companies

Bristol Myers Squibb Company

Alkermes plc

Eli Lilly and Company

Sanofi Genzyme

Genentech, Inc.

Additional Topics

United States BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window